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The PREDICT study was designed to assess the real-world and
long-term health-related quality of life in adults with chronic
migraine receiving onabotulinumtoxinA in Canada.1 There have
been several studies published on the long-term efﬁcacy and safety
of onabotulinumtoxinA after it was approved for clinical use in
chronic migraine patients based on the result from the PREEMPT
study.2 One study was the COMPEL study in which it established
signiﬁcance with headache days reduction and improvement
in disability based on the Headache Impact Test (HIT-6) and
Migraine Disability Assessment Questionnaire (MIDAS) over a
span of 108 weeks.3 The REPOSE study demonstrated long-term
(24 months) real-world data on effectiveness of onabotulinumtoxinA with sustained reduction in headache days frequency and
signiﬁcant improvement in quality-of-life measures.4 However,
these studies enrolled non-Canadian populations.
The PREDICT study is a multicenter, prospective study with
data collected across headache/pain centers in Canada. Appropriate screening was performed with a 4-week baseline period.
Treatments were based on the PREEMPT paradigm,2 155 units of
onabotulinumtoxinA administered at 31 ﬁxed sites with optional
additional injections for a total dose of 195 units (follow the pain
pattern). The PREDICT study was an observational study; hence,
no formal sample size calculations were formed, or no formal
hypothesis was tested.
The PREDICT study was able to demonstrate improvement in
quality of life through a self-administered questionnaire known as
Migraine-Speciﬁc Quality of Life Questionnaire (MSQ) which
was a clinical outcome used in the REPOSE study.4 The MSQ
has its strength in exploring different domains, including role
function restrictive, preventive, and emotional function. The
PREDICT study further supports previous chronic migraine
onabotulinumtoxinA studies, including reduction in headache
days per month, reduction in moderate or severe headache days
per month, and no new reported treatment-related adverse events.
As for the baseline demographics, it is comparable to other
onabotulinumtoxinA studies for chronic migraine, including age,
gender, age at diagnosis, and number of headache days per
month,3–5 with the exception of the following: There is a
signiﬁcant higher Caucasian representation (close to 95% vs.
around 80% in other studies),3–5 and 60% of the patients reported
a positive family history of chronic migraine, which may be a
reporting bias since the prevalence of chronic migraine in the
general population is less than 2%.6
Other limitations to consider: the PREEMPT injection paradigm was not monitored and physicians could deviate from these
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recommendations. There was no placebo or comparator arm.
There could be a signiﬁcant recall bias and high drop-off rates
since the PREDICT study was a long-term observational study.
The participants remaining in the study at the later time points
were likely to report a biased positive opinion on the treatment
response. All three MSQ domains achieved more than the minimal important differences. However, not all outcomes were
collected at each treatment visit. For example: MSQ and physician satisfaction were only collected at treatment 4 and ﬁnal visit.
Also, the impact on MSQ in patients who discontinued treatment
was unavailable; hence, a conclusion could not be drawn toward
response before treatment 4, between treatment 4 and ﬁnal visit,
and patients who discontinued midway.
The discontinuation rates for the pooled PREEMPT studies were
10%–12% for the 24-week double-blind phase and 25%–29% for
the 56-week open-label phase.2 In the PREDICT study, the total rate
was 38% likely a result of the real-world study design and the length
of the observation.
The majority of the participants were overusing acute medications (mean: 16.8 days per month). These participants likely had a
coexisting diagnosis of medication overuse headache based on
the International Classiﬁcation of Headache Disorders 3rd
edition.7 The reduction of acute medication use was not reported.
If this parameter was signiﬁcant, it could have an impact on the
MSQ outcome as well.
Patients who were taking oral preventatives were included in
the study; however, the PREDICT study did not collect information on the potential changes or adjustment of oral preventatives
within the 2-year period. An adjustment to an oral preventative
may impact the clinical outcome. For example, an anti-depressant
such as amitriptyline or nortriptyline may improve quality of life
through better sleep and/or mood.
This study was sponsored by Allergan (now AbbVie) which is
the manufacturer of onabotulinumtoxinA (Botox), and many
authors of this study reported ﬁnancial and/or nonﬁnancial conﬂicts of interest with Allergan (now AbbVie).
Overall, the PREDICT study was a well-designed study in
consideration of the limitations stated and being an open-label
observational long-term follow-up study. In the real-world
setting, it is not uncommon that onabotulinumtoxinA is used to
manage patients with chronic daily headaches, such as chronic
migraine patients with everyday headaches. The outcome may
not be a reduction in headache or migraine days, but possibly
headache intensity and/or quality of life and disability. The
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impact on quality of life of chronic migraine in the Canadian
population is limited and PREDICT results are relevant and
applicable. As stated in the PREDICT study, future analysis
from their data collection will explore the impact of onabotulinumtoxinA treatment for chronic migraine on health resource
utilization and medication overuse in which these measures may
also be appropriate for the real-world setting.
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